Chronic kidney disease
Conditions
Interventions
Azilsartan 20mg/day for 12 weeks
Candesartan 8mg/day for 12 weeks
Sponsors
Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinic SBP >130mmHg, clinic DBP >80mmHg or using anti-hypertensive drugs 2. Urinary protein creatinine ratio > 0.3g/gCr 3. eGFR >=15mL/min/1.73 m2
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. History of hypersensitivity to azilsartan or candesartan 3. Myocardial infarction or stroke in the past 6 months 4. Potassium >= 5.5 mEq/L 5. During lactating 6. Liver dysfunction (ALT > 3-times the upper limit of normal) 7. IgA nephropathy starting steroid therapy within 1 year 8. Known bilateral renal artery stenosis 9. Severe nephrotic syndrome (serum alb < 2g/dL) 10. Active cancer 11. Severe infection 12. Judged as inappropriate for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the difference of the percent changes in urinary protein creatinine ratio between two treatment groups | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes of blood pressure 2. Changes of urinary protein creatinine ratio 3. eGFR 4. Changes of urinary angiotensinogen, urinary 8-OHdG, serum osteopontin, plasma MCP-1 and serum IL-6 5. Changes of urinary protein creatinine ratio and blood pressure after switching ARB, ACEI or DRI to azilsartan | — |
Countries
Japan
Contacts
Public ContactTakaichi Suehiro
Kyushu University Department of Medicine and Clinical Science, Graduate School of Medical Sciences
Outcome results
None listed